Candidemia in children: Epidemiology, prevention and management

Mycoses

Volumn 61, Issue 9, 2018, Pages 614-622

  Mantadakis, Elpis ^a   Pana, Zoe Dorothea ^b   Zaoutis, Theoklis ^c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Aristotle University and Hippokration General Hospital   (Greece)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antifungal agents; Candida spp.; candidemia; insertion and maintenance bundles; paediatric intensive care

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CHLORHEXIDINE; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PROBIOTIC AGENT; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL THERAPY; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA AURIS; CANDIDA GLABRATA; CANDIDA HAEMULONII; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER INFECTION; CATHETER REMOVAL; CHILD; CRITICALLY ILL PATIENT; DIABETES MELLITUS; GRAFT RECIPIENT; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTESTINE; INVASIVE CANDIDIASIS; KIDNEY DISEASE; LEUKEMIA; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PARENTERAL NUTRITION; PATIENT HISTORY OF SURGERY; PEDIATRIC INTENSIVE CARE UNIT; PICHIA KUDRIAVZEVII; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; RHODOTORULA GLUTINIS; ADULT; CROSS INFECTION; DISEASE MANAGEMENT; GLOBAL HEALTH; INFANT; INFECTION CONTROL; NEWBORN; PROCEDURES; YOUNG ADULT;

ADULT; CANDIDEMIA; CROSS INFECTION; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFECTION CONTROL; YOUNG ADULT;

EID: 85047793728     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12792     Document Type: Review

References (103)

1. Raymond J, Aujard Y. Nosocomial infections in pediatric patients: a European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol. 2000;21:260-263.
2. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167:695-701.
3. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J. 2003;22:686-691.
4. Hacimustafaoglu M, Celebi S. Candida infections in non-neutropenic children after the neonatal period. Expert Rev Anti Infect Ther. 2011;9:923-940.
5. Gokcebay DG, Yarali N, Isik P, et al. Candida associated bloodstream infections in pediatric hematology patients: a single center experience. Mediterr J Hematol Infect Dis. 2016;8:e2016018.
6. Tsai MH, Hsu JF, Chu SM, et al. Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia. Sci Rep. 2017;7:1083.
7. Nallasamy K, Singhi SC. Tackling candidemia in pediatric intensive care units. a global concern!. Indian J Pediatr. 2014;81:1139-1140.
8. Singhi S, Deep A. Invasive candidiasis in pediatric intensive care units. Indian J Pediatr. 2009;76:1033-1044.
9. Tragiannidis A, Tsoulas C, Groll AH. Invasive candidiasis and candidaemia in neonates and children: update on current guidelines. Mycoses. 2015;58:10-21.
10. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-1239.
11. Harrington R, Kindermann SL, Hou Q, Taylor RJ, Azie N, Horn DL. Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients. Curr Med Res Opin. 2017;33:1803-1812.
12. Moran C, Grussemeyer CA, Spalding JR, Benjamin DK Jr, Reed SD. Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J. 2009;28:433-435.
13. Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123:1360-1368.
14. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695-1703.
15. Garcia-San Miguel L, Cobo J, Martos I, et al. Risk factors for candidemia in pediatric patients with congenital heart disease. Infect Control Hosp Epidemiol. 2006;27:576-580.
16. San Miguel LG, Cobo J, Otheo E, et al. Candidemia in pediatric patients with congenital heart disease. Diagn Microbiol Infect Dis. 2006;55:203-207.
17. Nucci M, Queiroz-Telles F, Alvarado-Matute T, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS ONE. 2013;8:e59373.
18. Ota KV, McGowan KL. Declining incidence of candidemia in a tertiary inpatient pediatric population. J Clin Microbiol. 2012;50:1048-1050.
19. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012;55:1352-1361.
20. Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS ONE. 2015;10:e0120452.
21. Benedict K, Roy M, Kabbani S, et al. Neonatal and pediatric candidemia: results from population-based active laboratory surveillance in four US locations, 2009-2015. J Pediatric Infect Dis Soc. 2018. https://doi.org/10.1093/jpids/piy009.
22. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001;33:1959-1967.
23. Brissaud O, Guichoux J, Harambat J, Tandonnet O, Zaoutis T. Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care. 2012;2:6.
24. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5-10.
25. Sutcu M, Acar M, Genc GE, et al. Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis. Turk Pediatri Ars. 2017;52:145-153.
26. Steinbach WJ, Roilides E, Berman D, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;31:1252-1257.
27. Zaoutis T. Candidemia in children. Curr Med Res Opin. 2010;26:1761-1768.
28. Pammi M, Holland L, Butler G, Gacser A, Bliss JM. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J. 2013;32:e206-216.
29. Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95-105.
30. Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis. 1998;26:1086-1088.
31. Chan S, Baley ED, Hossain J, Di Pentima MC. Candida species bloodstream infections in hospitalised children: a 10-year experience. J Paediatr Child Health. 2015;51:857-860; quiz 861.
32. Neu N, Malik M, Lunding A, et al. Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J. 2009;28:806-809.
33. Puig-Asensio M, Padilla B, Garnacho-Montero J, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clinic Microbiol Infect. 2014;20:O245-254.
34. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol. 2005;26:548-552.
35. Tadec L, Talarmin JP, Gastinne T, et al. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study. Mycoses. 2016;59:296-303.
36. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643.
37. Awasthi AK, Jain A, Awasthi S, Ambast A, Singh K, Mishra V. Epidemiology and microbiology of nosocomial pediatric candidemia at a northern Indian tertiary care hospital. Mycopathologia. 2011;172:269-277.
38. Prasad PA, Fisher BT, Coffin SE, et al. Pediatric Risk Factors for Candidemia Secondary to Candida glabrata and Candida krusei Species. J Pediatric Infect Dis Soc. 2013;2:263-266.
39. Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13:e1006290.
40. Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis. 2012;74:323-331.
41. Dutta A, Palazzi DL. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J. 2011;30:664-668.
42. Dotis J, Prasad PA, Zaoutis T, Roilides E. Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children. Pediatr Infect Dis J. 2012;31:557-560.
43. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532-538.
44. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk Factors for Disseminated Candidiasis in Children with Candidemia. Pediatr Infect Dis J. 2004;23:635-641.
45. Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med. 2007;33:1272-1283.
46. Advani S, Reich NG, Sengupta A, Gosey L, Milstone AM. Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit. Clin Infect Dis. 2011;52:1108-1115.
47. Cugno C, Cesaro S. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep. 2012;4:e9.
48. Klatte JM, Newland JG, Jackson MA. Incidence, classification, and risk stratification for Candida central line-associated bloodstream infections in pediatric patients at a tertiary care children's hospital, 2000-2010. Infect Control Hosp Epidemiol. 2013;34:1266-1271.
49. Srinivasan A, Wang C, Srivastava DK, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:94-101.
50. Hegazi M, Abdelkader A, Zaki M, El-Deek B. Characteristics and risk factors of candidemia in pediatric intensive care unit of a tertiary care children's hospital in Egypt. J Infect Dev Ctries. 2014;8:624-634.
51. Agin H, Devrim I, Isguder R, et al. Risk factors for candidemia in pediatric intensive care unit patients. Indian J Pediatr. 2014;81:1158-1162.
52. Agrawal C, Biswas D, Gupta A, Chauhan BS. Antibiotic overuse as a risk factor for candidemia in an Indian pediatric ICU. Indian J Pediatr. 2015;82:530-536.
53. Ammann RA, Laws HJ, Schrey D, et al. Bloodstream infection in paediatric cancer centres–leukaemia and relapsed malignancies are independent risk factors. Eur J Pediatr. 2015;174:675-686.
54. Santolaya ME, Alvarado T, Queiroz-Telles F, et al. Active surveillance of candidemia in children from Latin America: a key requirement for improving disease outcome. Pediatr Infect Dis J. 2014;33:e40-44.
55. Stratman RC, Martin CA, Rapp RP, Berger R, Magnuson B. Candidemia incidence in recipients of parenteral nutrition. Nutr Clin Pract. 2010;25:282-289.
56. Zaoutis TE, Coffin SE, Chu JH, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J. 2005;24:736-739.
57. Saxena S, Gee J, Klieger S, et al. Invasive fungal disease in pediatric solid organ transplant recipients. J Pediatric Infect Dis Soc. 2017. https://doi.org/10.1093/jpids/pix041.
58. Singhi S, Rao DS, Chakrabarti A. Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med. 2008;9:91-95.
59. Vogiatzi L, Ilia S, Sideri G, et al. Invasive candidiasis in pediatric intensive care in Greece: a nationwide study. Intensive Care Med. 2013;39:2188-2195.
60. Leon C, Alvarez-Lerma F, Ruiz-Santana S, et al. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study. Eur J Clin Microbiol Infect Dis. 2009;28:233-242.
61. Leroy G, Lambiotte F, Thevenin D, et al. Evaluation of “Candida score” in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care. 2011;1:50.
62. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis. 2010;51:e38-45.
63. Fisher BT, Ross RK, Roilides E, et al. Failure to Validate a Multivariable Clinical Prediction Model to Identify Pediatric Intensive Care Unit Patients at High Risk for Candidemia. J Pediatric Infect Dis Soc. 2016;5:458-461.
64. Steinbach WJ. Pediatric invasive candidiasis: epidemiology and diagnosis in children. J Fungi (Basel). 2016;2:pii: E5.
65. Playford EG, Lipman J, Jones M, et al. Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients. Clin Infect Dis. 2016;63:1463-1469.
66. Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis. 2008;27:1071-1078.
67. Rodriguez-Nunez A. Incidence and mortality of proven invasive Candida infections in pediatric intensive care patients. Infect Control Hosp Epidemiol. 2001;22:477-478.
68. Singhi SC, Reddy TCS, Chakrabarti A. Candidemia in a pediatric intensive care unit. Pediatr Crit Care Med. 2004;5:369-374.
69. Celebi S, Hacimustafaoglu M, Ozdemir O, Ozkaya G. Nosocomial candidaemia in children: results of a 9-year study. Mycoses. 2008;51:248-257.
70. Devrim I, Demirag B, Yaman Y, et al. A 7-year study of the distribution of nosocomial candidemia in children with cancer. Turk J Pediatr. 2015;57:225-229.
71. Wagner M, Bonhoeffer J, Erb TO, et al. Prospective study on central venous line associated bloodstream infections. Arch Dis Child. 2011;96:827-831.
72. Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18(Suppl 7):38-52.
73. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110-1122.
74. Janum S, Afshari A. Central venous catheter (CVC) removal for patients of all ages with candidaemia. Cochrane Database Syst Rev. 2016;7:CD011195.
75. Blackwood RA, Klein KC, Micel LN, et al. Ethanol locks therapy for resolution of fungal catheter infections. Pediatr Infect Dis J. 2011;30:1105-1107.
76. Oeser C, Lamagni T, Heath PT, Sharland M, Ladhani S. The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009. Pediatr Infect Dis J. 2013;32:23-26.
77. Miller MR, Griswold M, Harris JM 2nd, et al. Decreasing PICU catheter-associated bloodstream infections: NACHRI's quality transformation efforts. Pediatrics. 2010;125:206-213.
78. Miller MR, Niedner MF, Huskins WC, et al. Reducing PICU central line-associated bloodstream infections: 3-year results. Pediatrics. 2011;128:e1077-1083.
79. Ling ML, Apisarnthanarak A, Jaggi N, et al. APSIC guide for prevention of Central Line Associated Bloodstream Infections (CLABSI). Antimicrob Resist Infect Control. 2016;5:16.
80. Centers for Disease Control and Prevention (CDC). Vital signs: central line-associated blood stream infections–United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep. 2011;60:243-248.
81. Bundy DG, Gaur AH, Billett AL, et al. Preventing CLABSIs among pediatric hematology/oncology inpatients: national collaborative results. Pediatrics. 2014;134:e1678-1685.
82. Rinke ML, Bundy DG, Chen AR, et al. Central line maintenance bundles and CLABSIs in ambulatory oncology patients. Pediatrics. 2013;132:e1403-1412.
83. Wheeler DS, Giaccone MJ, Hutchinson N, et al. A hospital-wide quality-improvement collaborative to reduce catheter-associated bloodstream infections. Pediatrics. 2011;128:e995-e1004; quiz e1004-1007.
84. Antworth A, Collins CD, Kunapuli A, et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacotherapy. 2013;33:137-143.
85. Rinke ML, Chen AR, Bundy DG, et al. Implementation of a central line maintenance care bundle in hospitalized pediatric oncology patients. Pediatrics. 2012;130:e996-e1004.
86. Marschall J, Mermel LA, Fakih M, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:753-771.
87. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52:e162-193.
88. Mahida N. Hand hygiene compliance: are we kidding ourselves? J Hosp Infect. 2016;92:307-308.
89. Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284-1292.
90. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
91. Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19-37.
92. Cortegiani A, Russotto V, Maggiore A, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev. 2016;(1):CD004920.
93. Matsubara VH, Bandara HM, Mayer MP, Samaranayake LP. Probiotics as Antifungals in Mucosal Candidiasis. Clin Infect Dis. 2016;62:1143-1153.
94. Wagner RD, Pierson C, Warner T, et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun. 1997;65:4165-4172.
95. Manzoni P. Use of Lactobacillus casei subspecies Rhamnosus GG and gastrointestinal colonization by Candida species in preterm neonates. J Pediatr Gastroenterol Nutr. 2007;45(Suppl 3):S190-194.
96. Kumar S, Singhi S, Chakrabarti A, Bansal A, Jayashree M. Probiotic use and prevalence of candidemia and candiduria in a PICU. Pediatr Crit Care Med. 2013;14:e409-415.
97. Kumar S, Bansal A, Chakrabarti A, Singhi S. Evaluation of efficacy of probiotics in prevention of candida colonization in a PICU-a randomized controlled trial. Crit Care Med. 2013;41:565-572.
98. Milstone AM, Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013;381:1099-1106.
99. Gilbert RE, Mok Q, Dwan K, et al. Impregnated central venous catheters for prevention of bloodstream infection in children (the CATCH trial): a randomised controlled trial. Lancet. 2016;387:1732-1742.
100. Colombo AL, Guimaraes T, Sukienik T, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014;40:1489-1498.
101. VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Ann Pharmacother. 2010;44:166-177.
102. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50.
103. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433-444.